BELLUS Health Inc.

De la TradeVille.ro wiki
Versiunea din 29 septembrie 2024 17:08, autor: 127.0.0.1 (discuție) (The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).)
(dif) ← Versiunea anterioară | Versiunea curentă (dif) | Versiunea următoare → (dif)

Pagina dedicata companiei BELLUS Health Inc. listata cu simbolul US.BLU

Descriere companie

BELLUS Health Inc. (www.bellushealth.com) is a clinical stage pharmaceutical company that is focused on developing a P2X3 antagonist to address various afferent hypersensitization-related disorders. The Company’s lead candidate, BLU-5937, is being studied in Phase II clinical trials in refractory chronic cough and chronic pruritus associated with atopic dermatitis. It is developing BLU-5937 for the treatment of chronic cough and chronic pruritus, or chronic itch. The Company is focused on SOOTHE, which is in a Phase IIb trial of BLU-5937 in refractory chronic cough patients. It is also focused on BLUEPRINT, which is in a Phase II trial in chronic pruritus associated with atopic dermatitis. The RELIEF trial established proof-of-concept for BLU-5937 in the treatment of RCC patients.

Grafic actiuni companie

Ultimele stiri despre BELLUS Health Inc. (US.BLU)

Adus de la „https://wiki.tradeville.ro/index.php?title=BELLUS_Health_Inc.&oldid=447839”